Developed by Metabolic Pharmaceuticals in Australia, AOD-9604 was engineered to retain the fat-reducing properties of intact growth hormone while eliminating the undesirable effects on glucose metabolism, insulin sensitivity, and tissue growth
Additionally, patients with inflammatory bowel disease, severe gastroesophageal reflux disease, or other significant gastrointestinal disorders should be monitored closely if treatment is initiated, as the gastrointestinal effects of semaglutide may worsen their underlying condition
So having that technology to bypass this is somehow empowering that we can do that part
By utilizing a sustained-release formulation, it overcomes the historical challenges of oral bioavailability, providing a steady, reliable defense against the relentless oxidative stress that characterizes post-viral syndromes
Wogonin improves colitis by activating the AhR pathway to regulate the plasticity of ILC3/ILC1